pioglitazone has been researched along with Cancer of the Thyroid in 11 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "However, thyroid cancers that are progressive despite standard-of-care therapy appear to only rarely express PPFP." | 2.87 | Pioglitazone Therapy of PAX8-PPARγ Fusion Protein Thyroid Carcinoma. ( Caoili, EM; Giordano, TJ; Haugen, BR; Koenig, RJ; Shah, MH; Sherman, SI, 2018) |
| "Anaplastic cancer constitutes 1% of thyroid cancers, and it is one of the most aggressive cancers." | 1.56 | Effects of metformin and pioglitazone combination on apoptosis and AMPK/mTOR signaling pathway in human anaplastic thyroid cancer cells. ( Biray Avci, C; Caliskan Kurt, C; Erdogan, M; Gunduz, C; Ozdemir Kutbay, N; Sarer Yurekli, B; Shademan, B, 2020) |
| "Oral pioglitazone treatment was applied for 6 months." | 1.38 | Pioglitazone therapy in progressive differentiated thyroid carcinoma. ( Bockisch, A; Nagarajah, J; Rosenbaum-Krumme, SJ, 2012) |
| "Approximately 35% of follicular thyroid carcinomas harbor a chromosomal translocation that results in expression of a paired box gene 8-peroxisome proliferator-activated receptor γ gene (PPARγ) fusion protein (PPFP)." | 1.37 | Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARgamma fusion protein thyroid carcinoma. ( Colby, LA; Diallo-Krou, E; Dobson, ME; Giordano, TJ; Grachtchouk, V; Koenig, RJ; Wilkinson, JE; Yu, J, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Ozdemir Kutbay, N | 1 |
| Biray Avci, C | 1 |
| Sarer Yurekli, B | 1 |
| Caliskan Kurt, C | 1 |
| Shademan, B | 1 |
| Gunduz, C | 1 |
| Erdogan, M | 1 |
| Giordano, TJ | 2 |
| Haugen, BR | 1 |
| Sherman, SI | 1 |
| Shah, MH | 1 |
| Caoili, EM | 1 |
| Koenig, RJ | 5 |
| Vu-Phan, D | 1 |
| Grachtchouk, V | 3 |
| Yu, J | 4 |
| Colby, LA | 2 |
| Wicha, MS | 1 |
| Tseng, CH | 1 |
| Zhang, Y | 2 |
| Lee, C | 1 |
| Xu, B | 1 |
| Sartor, MA | 2 |
| Qin, T | 1 |
| Lumeng, CN | 1 |
| Antonelli, A | 1 |
| Ferrari, SM | 1 |
| Fallahi, P | 1 |
| Berti, P | 1 |
| Materazzi, G | 1 |
| Minuto, M | 1 |
| Giannini, R | 1 |
| Marchetti, I | 1 |
| Barani, L | 1 |
| Basolo, F | 1 |
| Ferrannini, E | 1 |
| Miccoli, P | 1 |
| Dobson, ME | 1 |
| Diallo-Krou, E | 1 |
| Wilkinson, JE | 1 |
| Nicolau Ramis, J | 1 |
| Masmiquel Comas, L | 1 |
| Rosenbaum-Krumme, SJ | 1 |
| Bockisch, A | 1 |
| Nagarajah, J | 1 |
| Fröhlich, E | 1 |
| Machicao, F | 1 |
| Wahl, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2 Study of Pioglitazone in Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene[NCT01655719] | Phase 2 | 1 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Toxicities experienced by patients with PAX8-PPARgamma fusion gene-positive follicular-patterned thyroid carcinomas treated with pioglitazone are indicated by presence of Serious Adverse Events (that show relatedness). (NCT01655719)
Timeframe: 24 weeks
| Intervention | serious adverse events (Number) |
|---|---|
| Pioglitazone Treatment | 0 |
Determine if pioglitazone decreases serum thyroglobulin in patients with follicular-patterned thyroid carcinomas that contain the PAX8-PPARgamma fusion gene. (NCT01655719)
Timeframe: Baseline and 24 weeks
| Intervention | ng/mL (Number) | |
|---|---|---|
| Baseline | 24 weeks | |
| Pioglitazone Treatment | 1974 | 49.4 |
Response is measured by change in Tumor size (cm) (NCT01655719)
Timeframe: Baseline and 24 weeks
| Intervention | cm (Number) | |
|---|---|---|
| Baseline | 24 weeks | |
| Pioglitazone Treatment | 6.0 | 3.9 |
1 trial available for pioglitazone and Cancer of the Thyroid
| Article | Year |
|---|---|
Pioglitazone Therapy of PAX8-PPARγ Fusion Protein Thyroid Carcinoma.
Topics: Adenoma, Oxyphilic; Aged, 80 and over; Antineoplastic Agents; Humans; Male; Mutation; Oncogene Prote | 2018 |
10 other studies available for pioglitazone and Cancer of the Thyroid
| Article | Year |
|---|---|
Effects of metformin and pioglitazone combination on apoptosis and AMPK/mTOR signaling pathway in human anaplastic thyroid cancer cells.
Topics: AMP-Activated Protein Kinases; Apoptosis; Cell Line, Tumor; Drug Therapy, Combination; Gene Expressi | 2020 |
The thyroid cancer PAX8-PPARG fusion protein activates Wnt/TCF-responsive cells that have a transformed phenotype.
Topics: Animals; Cell Line; Cell Line, Tumor; Humans; Mice; Mice, Transgenic; Oncogene Proteins, Fusion; Pai | 2013 |
Pioglitazone and thyroid cancer risk in Taiwanese patients with type 2 diabetes 2.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Mal | 2014 |
Genomic binding and regulation of gene expression by the thyroid carcinoma-associated PAX8-PPARG fusion protein.
Topics: Animals; Biomarkers, Tumor; Chromatin Immunoprecipitation; Flow Cytometry; Gene Expression Regulatio | 2015 |
Genomic binding of PAX8-PPARG fusion protein regulates cancer-related pathways and alters the immune landscape of thyroid cancer.
Topics: Adenocarcinoma, Follicular; Animals; Binding Sites; Chromatin Immunoprecipitation; Disease Models, A | 2017 |
Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells.
Topics: Carcinoma; Cell Proliferation; Growth Inhibitors; Humans; Pioglitazone; Rosiglitazone; Thiazolidined | 2009 |
Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARgamma fusion protein thyroid carcinoma.
Topics: Adenocarcinoma, Follicular; Adipogenesis; Animals; Mice; Mice, Transgenic; Oncogene Proteins, Fusion | 2011 |
[The new antidiabetic agents in the firing line.... safety reasons or witch hunt?].
Topics: Animals; Breast Neoplasms; Calcitonin; Carcinoma, Medullary; Clinical Trials as Topic; Comorbidity; | 2012 |
Pioglitazone therapy in progressive differentiated thyroid carcinoma.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Pioglita | 2012 |
Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture.
Topics: Adenocarcinoma, Follicular; Animals; Annexin A5; Apoptosis; Cell Differentiation; Cell Line, Transfo | 2005 |